Treatment options in colchicine resistant familial Mediterranean fever patients: Thalidomide and etanercept as adjunctive agents

E. Seyahi, H. Ozdogan, S. Celik, S. Ugurlu, H. Yazici

Division of Rheumatology, Department of Medicine, Cerrahpasa Medical Faculty, University of Istanbul, Istanbul, Turkey

2006 Vol.24, N°5 ,Suppl.42 - PI 0099, PF 0103
Full Papers

Free to view (click on article PDF icon to read the article)

Rheumatology Article



Regular colchicine treatment cannot control the typical febrile attacks of FMF in about 5-10% of the compliant patients. Here we report the effect of thalidomide and etanercept in 5 colchicine-resistant cases.
Five (4M/ 1F) FMF patients between April 2005 and March 2006, who were experiencing at least 2 attacks per month, despite regular colchicine were included to the study. Four male patients were given thalidomide 100 mg/d initially. Two of these patients unresponsive to thalidomide were prescribed subcutaneous injections of etanercept 25 mg, twice a week. The female patient received etanercept as the first choice due to potential side effects. She then had to be converted to thalidomide due to a severe injection site reaction.
The median follow up period with thalidomide and etanercept was 8 months. Both thalidomide and etanercept lowered the number of the abdominal attacks.
Thalidomide and etanercept might be effective as additional treatment in colchicine-resistant cases of FMF.

PMID: 17067437 [PubMed]